Molekulare Brustbildgebung
详细信息 查看全文
- 作者：K. Pinker (1)
Prof. Dr. T.H. Helbich MBA ; MSc. (1)
H. Magometschnigg (1)
B. Fueger (1) (2)
P. Baltzer (1) - 关键词：Brusttumoren ; Magnetresonanztomographie (MRT) ; Nuklearmedizinische Bildgebung ; MR ; Spektroskopie ; Radiotracer ; Breast tumor ; Magnetic resonance imaging (MRI) ; Nuclear imaging ; MR spectroscopy ; Radiotracers
- 刊名：Der Radiologe
- 出版年：2014
- 出版时间：March 2014
- 年：2014
- 卷：54
- 期：3
- 页码：241-253
- 全文大小：1,267 KB
- 参考文献：1. Ackerstaff E, Glunde K, Bhujwalla ZM (2003) Choline phospholipid metabolism: a target in cancer cells? J Cell Biochem 90:525鈥?33
2. Adejolu M, Huo L, Rohren E et al (2012) False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol 198:W304鈥揥314
3. Aktolun C, Bayhan H, Kir M (1992) Clinical experience with Tc-99m MIBI imaging in patients with malignant tumors. Preliminary results and comparison with Tl-201. Clin Nucl Med 17:171鈥?76
4. Antoch G, Saoudi N, Kuehl H et al (2004) Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 22:4357鈥?368
5. Ardenkjaer-Larsen JH, Fridlund B, Gram A et al (2003) Increase in signal-to-noise ratio of >鈥?0,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 100:10158鈥?0163
6. Arias-Mendoza F, Payne GS, Zakian KL et al (2006) In vivo 31P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR Biomed 19:504鈥?12
7. Arslan N, Ozturk E, Ilgan S et al (1999) 99Tcm-MIBI scintimammography in the evaluation of breast lesions and axillary involvement: a comparison with mammography and histopathological diagnosis. Nucl Med Commun 20:317鈥?25
8. Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 18:3495鈥?502
9. Baltzer PA, Dietzel M (2013) Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T 鈥?systematic review and meta-analysis. Radiology 267:735鈥?46
10. Barzilai A, Horowitz A, Geier A et al (1991) Phosphate metabolites and steroid hormone receptors of benign and malignant breast tumors. A nuclear magnetic resonance study. Cancer 67:2919鈥?925
11. Becherer A, Helbich T, Staudenherz A et al (1997) The diagnostic value of planar and SPET scintimammography in different age groups. Nucl Med Commun 18:710鈥?18
12. Been LB, Elsinga PH, De Vries J et al (2006) Positron emission tomography in patients with breast cancer using (18)F-3鈥?deoxy-3鈥?fluoro-l-thymidine ((18)F-FLT) 鈥?a pilot study. Eur J Surg Oncol 32:39鈥?3
13. Bensch F, Van Kruchten M, Lamberts LE et al (2013) Molecular imaging for monitoring treatment response in breast cancer patients. Eur J Pharmacol 717:2鈥?1
14. Berg WA, Madsen KS, Schilling K et al (2012) Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR Am J Roentgenol 198:219鈥?32
15. Berg WA, Weinberg IN, Narayanan D et al (2006) High-resolution fluorodeoxyglucose positron emission tomography with compression (鈥瀙ositron emission mammography鈥? is highly accurate in depicting primary breast cancer. Breast J 12:309鈥?23
16. Bickel H, Pinker K, Bogner W et al (2012) Diffusion-weighted imaging: a noninvasive biomarker for breast cancer invasiveness. RSNA, Chicago
17. Birdwell RL, Mountford CE, Iglehart JD (2010) Molecular imaging of the breast. Radiol Clin North Am 48:1075鈥?088
18. Blankenberg FG (2008) In vivo detection of apoptosis. J Nucl Med 49(Suppl 2):81S鈥?5S
19. Bogner W, Gruber S, Pinker K et al (2009) Diffusion-weighted MR for differentiation of breast lesions at 3.0聽T: how does selection of diffusion protocols affect diagnosis? Radiology 253:341鈥?51
20. Bogner W, Pinker-Domenig K, Bickel H et al (2012) Readout-segmented echo-planar imaging improves the diagnostic performance of diffusion-weighted MR breast examinations at 3.0聽T. Radiology 263:64鈥?6
21. Brem RF, Fishman M, Rapelyea JA (2007) Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: a comparative study. Acad Radiol 14:945鈥?50
22. Brem RF, Floerke AC, Rapelyea JA et al (2008) Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology 247:651鈥?57
23. Brem RF, Rapelyea JA, Zisman G et al (2005) Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology 237:274鈥?80
24. Brindle K (2008) New approaches for imaging tumour responses to treatment. Nat Rev Cancer 8:94鈥?07
25. Brindle KM, Bohndiek SE, Gallagher FA et al (2011) Tumor imaging using hyperpolarized 13C magnetic resonance spectroscopy. Magn Reson Med 66:505鈥?19
26. Brown R, Storey P, Geppert C et al (2013) Breast MRI at 7聽Tesla with a bilateral coil and T1-weighted acquisition with robust fat suppression: image evaluation and comparison with 3聽Tesla. Eur Radiol 23:2969鈥?978
27. Cheng J, Lei L, Xu J et al (2013) 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 54:333鈥?40
28. Cooper KL, Harnan S, Meng Y et al (2011) Positron emission tomography (PET) for assessment of axillary lymph node status in early breast cancer: a systematic review and meta-analysis. Eur J Surg Oncol 37:187鈥?98
29. Coover LR, Caravaglia G, Kuhn P (2004) Scintimammography with dedicated breast camera detects and localizes occult carcinoma. J Nucl Med 45:553鈥?58
30. Cutrone JA, Khalkhali I, Yospur LS et al (1999) Tc-99m sestamibi scintimammography for the evaluation of breast masses in patients with radiographically dense breasts. Breast J 5:383鈥?88
31. Day SE, Kettunen MI, Cherukuri MK et al (2011) Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med 65:557鈥?63
32. Domingues RC, Carneiro MP, Lopes FC et al (2009) Whole-body MRI and FDG PET fused images for evaluation of patients with cancer. AJR Am J Roentgenol 192:1012鈥?020
33. Ei Khouli RH, Jacobs MA, Mezban SD et al (2010) Diffusion-weighted imaging improves the diagnostic accuracy of conventional 3.0-T breast MR imaging. Radiology 256:64鈥?3
34. Escalona S, Blasco JA, Reza MM et al (2009) A systematic review of FDG-PET in breast cancer. Med Oncol 27:114鈥?29
35. Fletcher JW, Djulbegovic B, Soares HP et al (2008) Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 49:480鈥?08
36. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012鈥?021
37. Gallagher FA, Bohndiek SE, Kettunen MI et al (2011) Hyperpolarized 13C MRI and PET: in vivo tumor biochemistry. J Nucl Med 52:1333鈥?336
38. Gallagher FA, Kettunen MI, Brindle KM (2011) Imaging pH with hyperpolarized 13C. NMR Biomed 24:1006鈥?015
39. Glass SB, Shah ZA (2013) Clinical utility of positron emission mammography. Proceedings 26:314鈥?19
40. Golman K, Petersson JS (2006) Metabolic imaging and other applications of hyperpolarized 13C1. Acad Radiol 13:932鈥?42
41. Golman K, Zandt RI, Lerche M et al (2006) Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 66:10855鈥?0860
42. Goto M, Ito H, Akazawa K et al (2007) Diagnosis of breast tumors by contrast-enhanced MR imaging: comparison between the diagnostic performance of dynamic enhancement patterns and morphologic features. J Magn Reson Imaging 25:104鈥?12
43. Gruber S, Debski BK, Pinker K et al (2011) Three-dimensional proton MR spectroscopic imaging at 3聽T for the differentiation of benign and malignant breast lesions. Radiology 261:752鈥?61
44. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57鈥?0
45. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646鈥?74
46. Helbich TH, Becherer A, Trattnig S et al (1997) Differentiation of benign and malignant breast lesions: MR imaging versus Tc-99m sestamibi scintimammography. Radiology 202:421鈥?29
47. Judenhofer MS, Wehrl HF, Newport DF et al (2008) Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med14:459鈥?65
48. Kalinyak JE, Berg WA, Schilling K et al (2013) Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. Eur J Nucl Med Mol Imaging [Epub ahead of print]
49. Kalles V, Zografos GC, Provatopoulou X et al (2013) The current status of positron emission mammography in breast cancer diagnosis. Breast Cancer 20:123鈥?30
50. Kenny L, Coombes RC, Vigushin DM et al (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3鈥?deoxy-3鈥?[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339鈥?347
51. Keshari KR, Sai V, Wang ZJ et al (2013) Hyperpolarized [1鈥?3C]dehydroascorbate MR spectroscopy in a murine model of prostate cancer: comparison with 18F-FDG PET. J Nucl Med 54:922鈥?28
52. Keshari KR, Sriram R, Koelsch BL et al (2013) Hyperpolarized 13C-pyruvate magnetic resonance reveals rapid lactate export in metastatic renal cell carcinomas. Cancer Res 73:529鈥?38
53. Khalkhali I, Mena I, Diggles L (1994) Review of imaging techniques for the diagnosis of breast cancer: a new role of prone scintimammography using technetium-99m sestamibi. Eur J Nucl Med 21:357鈥?62
54. Klomp DW, Van De Bank BL, Raaijmakers A et al (2011) 31P MRSI and 1H MRS at 7聽T: initial results in human breast cancer. NMR Biomed 24:1337鈥?342
55. Korteweg MA, Veldhuis WB, Visser F et al (2011) Feasibility of 7聽Tesla breast magnetic resonance imaging determination of intrinsic sensitivity and high-resolution magnetic resonance imaging, diffusion-weighted imaging, and (1)H-magnetic resonance spectroscopy of breast cancer patients receiving neoadjuvant therapy. Invest Radiol 46:370鈥?76
56. Krause BJ, Schwarzenbock S, Schwaiger M (2010) Tracers in oncology 鈥?preclinical and clinical evaluation. Nuklearmedizin. Nuklearmedizin 49(Suppl 1):S41鈥揝45
57. Kuhl CK, Jost P, Morakkabati N et al (2006) Contrast-enhanced MR imaging of the breast at 3.0 and 1.5聽T in the same patients: initial experience. Radiology 239:666鈥?76
58. Kuhl CK, Schild HH, Morakkabati N (2005) Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution. Radiology 236:789鈥?00
59. Kul S, Cansu A, Alhan E et al (2011) Contribution of diffusion-weighted imaging to dynamic contrast-enhanced MRI in the characterization of breast tumors. AJR Am J Roentgenol 196:210鈥?17
60. Kumar R, Lal N, Alavi A (2007) 18F-FDG PET in detecting primary breast cancer. J Nucl Med 48:1751 (author reply 1752)
61. Kurhanewicz J, Vigneron DB, Brindle K et al (2011) Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 13:81鈥?7
62. Linden HM, Dehdashti F (2013) Novel methods and tracers for breast cancer imaging. Semin Nucl Med 43:324鈥?29
63. Madelin G, Regatte RR (2013) Biomedical applications of sodium MRI in vivo. J Magn Reson Imaging 38:511鈥?29
64. Maffioli L, Agresti R, Chiti A et al (1996) Prone scintimammography in patients with non-palpable breast lesions. Anticancer Res 16:1269鈥?273
65. Martincich L, Deantoni V, Bertotto I et al (2012) Correlations between diffusion-weighted imaging and breast cancer biomarkers. Eur Radiol 22:1519鈥?528
66. Mortimer JE, Bading JR, Colcher DM et al (2014) Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using 64Cu-DOTA-trastuzumab PET. J Nucl Med 55:23鈥?9
67. Moy L, Noz ME, Maguire GQ Jr et al (2007) Prone mammoPET acquisition improves the ability to fuse MRI and PET breast scans. Clin Nucl Med 32:194鈥?98
68. Moy L, Ponzo F, Noz ME et al (2007) Improving specificity of breast MRI using prone PET and fused MRI and PET 3D volume datasets. J Nucl Med 48:528鈥?37
69. Ouwerkerk R (2011) Sodium MRI. Methods Mol Biol 711:175鈥?01
70. Ouwerkerk R, Jacobs MA, Macura KJ et al (2007) Elevated tissue sodium concentration in malignant breast lesions detected with non-invasive 23Na MRI. Breast Cancer Res Treat 106:151鈥?60
71. Padhani AR (2005) Where are we with imaging oxygenation in human tumours? Cancer Imaging 5:128鈥?30
72. Partridge SC, Mullins CD, Kurland BF et al (2010) Apparent diffusion coefficient values for discriminating benign and malignant breast MRI lesions: effects of lesion type and size. AJR Am J Roentgenol 194:1664鈥?673
73. Penuelas I, Dominguez-Prado I, Garcia-Velloso MJ et al (2012) PET tracers for clinical imaging of breast cancer. J Oncol 2012:710561
74. Pereira FP, Martins G, Carvalhaes De Oliveira Rde V (2011) Diffusion magnetic resonance imaging of the breast. Magn Reson Imaging Clin N Am 19:95鈥?10
75. Pichler BJ, Judenhofer MS, Wehrl HF (2008) PET/MRI hybrid imaging: devices and initial results. Eur Radiol 18:1077鈥?086
76. Pinker K, Bickel H, Helbich T et al (2013) Combined contrast enhanced magnetic resonance and diffusion weighted imaging reading adapted to the 鈥濨reast Imaging Reporting and Data System鈥?for multiparametric 3聽T imaging of breast lesions. Eur Radiol 23:1791鈥?802
77. Pinker K, Bogner W, Baltzer P et al (2014) Improved diagnostic accuracy with multiparametric magnetic resonance imaging of the breast using dynamic contrast-enhanced MRI, diffusion-weighted imaging and 3D proton MR spectroscopic imaging. Invest Radiol (in press)
78. Pinker K, Bogner W, Baltzer P et al (2013) Clinical application of bilateral high temporal and spatial resolution dynamic contrast-enhanced magnetic resonance imaging of the breast at 7聽T. Eur Radiol (in press)
79. Pinker K, Bogner W, Gruber S et al (2011) Molecular imaging in breast cancer 鈥?potential future aspects. Breast Care (Basel) 6:110鈥?19
80. Pinker K, Grabner G, Bogner W et al (2009) A combined high temporal and high spatial resolution 3聽Tesla MR imaging protocol for the assessment of breast lesions: initial results. Invest Radiol 44:553鈥?58
81. Pinker K, Magometschnigg H, Bogner W et al (2012) Multiparametric PET-MRI of breast tumors at 3聽T obviates unnecessary breast biopsies. WMIC Dublin, Ireland
82. Pinker K, Stadlbauer A, Bogner W et al (2012) Molecular imaging of cancer: MR spectroscopy and beyond. Eur J Radiol 81:566鈥?77
83. Pinker-Domenig K, Bogner W, Gruber S et al (2011) High resolution MRI of the breast at 3聽T: which BI-RADS(R) descriptors are most strongly associated with the diagnosis of breast cancer? Eur Radiol 22:322鈥?30
84. Quon A, Gambhir SS (2005) FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23:1664鈥?673
85. Rajendran JG (2004) Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10:2245鈥?252
86. Rhodes DJ, O鈥檆onnor MK, Phillips SW et al (2005) Molecular breast imaging: a new technique using technetium Tc 99m scintimammography to detect small tumors of the breast. Mayo Clin Proc 80:24鈥?0
87. Rosenkrantz AB, Deng FM, Kim S et al (2012) Prostate cancer: multiparametric MRI for index lesion localization 鈥?a multiple-reader study. AJR Am J Roentgenol 199:830鈥?37
88. Rosenkrantz AB, Mussi TC, Borofsky MS et al (2012) 3.0聽T multiparametric prostate MRI using pelvic phased-array coil: utility for tumor detection prior to biopsy. Urol Oncol 31:1430鈥?435
89. Roy B, Gupta RK, Maudsley AA et al (2013) Utility of multiparametric 3-T MRI for glioma characterization. Neuroradiology 55:603鈥?10
90. Ruibal A, Benlloch JM, Olmos RV et al (2012) Molecular imaging in breast cancer. J Oncol 2012:426260
91. Sauter AW, Wehrl HF, Kolb A et al (2010) Combined PET/MRI: one step further in multimodality imaging. Trends Mol Med 16:508鈥?15
92. Sciarra A, Panebianco V, Cattarino S et al (2012) Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy. BJU Int 110:1661鈥?665
93. Scopinaro F, Schillaci O, Ussof W et al (1997) A three center study on the diagnostic accuracy of 99mTc-MIBI scintimammography. Anticancer Res 17:1631鈥?634
94. Smith-Jones PM, Solit D, Afroze F et al (2006) Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. J Nucl Med 47:793鈥?96
95. Smith-Jones PM, Solit DB, Akhurst T et al (2004) Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol 22:701鈥?06
96. Stadlbauer A, Bernt R, Gruber S et al (2009) Diffusion-weighted MR imaging with background body signal suppression (DWIBS) for the diagnosis of malignant and benign breast lesions. Eur Radiol 19:2349鈥?356
97. Stehouwer BL, Klomp DW, Korteweg MA et al (2013) 7聽T versus 3聽T contrast-enhanced breast magnetic resonance imaging of invasive ductulolobular carcinoma: first clinical experience. Magn Reson Imaging 31:613鈥?17
98. Stehouwer BL, Klomp DW, Van Den Bosch MA et al (2013) Dynamic contrast-enhanced and ultra-high-resolution breast MRI at 7.0聽Tesla. Eur Radiol 23:2961鈥?968
99. Sun Y, Wei W, Yang HW et al (2013) Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. Eur J Nucl Med Mol Imaging 40:450鈥?63
100. Taillefer R (2005) Clinical applications of 99mTc-sestamibi scintimammography. Semin Nucl Med 35:100鈥?15
101. Tamura K, Kurihara H, Yonemori K et al (2013) 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J Nucl Med 54:1869鈥?875
102. Umutlu L, Maderwald S, Kraff O et al (2010) Dynamic contrast-enhanced breast MRI at 7聽Tesla utilizing a single-loop coil: a feasibility trial. Acad Radiol 17:1050鈥?056
103. Van Kruchten M, De Vries EG, Brown M et al (2013) PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol 14:e465鈥揺475
104. Vomweg TW, Teifke A, Schreiber WG et al (2002) Combination of low and high resolution T1-weighted sequences for improved evaluation of morphologic criteria in dynamic contrast enhanced MRI of the breast. Rofo 174:1445鈥?449
105. Wang MW, Wang F, Zheng YJ et al (2013) An in vivo molecular imaging probe (18)F-Annexin B1 for apoptosis detection by PET/CT: preparation and preliminary evaluation. Apoptosis 18:238鈥?47
106. Wehrl HF, Judenhofer MS, Wiehr S et al (2009) Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging 36(Suppl 1):S56鈥揝68
107. Wehrl HF, Sauter AW, Judenhofer MS et al (2010) Combined PET/MR imaging 鈥?technology and applications. Technol Cancer Res Treat 9:5鈥?0
108. Weissleder R, Mahmood U (2001) Molecular imaging. Radiology 219:316鈥?33
109. Wijnen JP, Van Der Kemp WJ, Luttje MP et al (2011) Quantitative (31) P magnetic resonance spectroscopy of the human breast at 7聽T. Magn Reson Med 68:339鈥?48
110. Woodhams R, Matsunaga K, Iwabuchi K et al (2005) Diffusion-weighted imaging of malignant breast tumors 鈥?the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Tomography 29:644鈥?49
111. Woodhams R, Matsunaga K, Kan S et al (2005) ADC mapping of benign and malignant breast tumors. J Magn Reson Med Sci 4:35鈥?2
112. Yabuuchi H, Matsuo Y, Kamitani T et al (2010) Non-mass-like enhancement on contrast-enhanced breast MR imaging: lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. Eur J Radiol 75:e126鈥揺132
113. Yabuuchi H, Matsuo Y, Okafuji T et al (2008) Enhanced mass on contrast-enhanced breast MR imaging: Lesion characterization using combination of dynamic contrast-enhanced and diffusion-weighted MR images. J Magn Reson Imaging 28:1157鈥?165
114. Yang Z, Sun Y, Zhang Y et al (2013) Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo? Clin Breast Cancer 13:359鈥?63 - 作者单位：K. Pinker (1)
Prof. Dr. T.H. Helbich MBA, MSc. (1)
H. Magometschnigg (1)
B. Fueger (1) (2)
P. Baltzer (1)
1. Abteilung f眉r Molekulare Bildgebung, Universit盲tsklinik f眉r Radiologie und Nuklearmedizin, Medizinische Universit盲t Wien, W盲hringer G眉rtel 18鈥?0, 1090, Wien, 脰sterreich
2. Abteilung f眉r Nuklearmedizin, Universit盲tsklinik f眉r Radiologie und Nuklearmedizin, Medizinische Universit盲t Wien, Wien, 脰sterreich - ISSN：1432-2102
文摘
Clinical/methodical issue The aim of molecular imaging is to visualize and quantify biological, physiological and pathological processes at cellular and molecular levels. Molecular imaging using various techniques has recently become established in breast imaging. Standard radiological methods Currently molecular imaging techniques comprise multiparametric magnetic resonance imaging (MRI) using dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI), proton MR spectroscopy (1H-MRSI), nuclear imaging by breast-specific gamma imaging (BSGI), positron emission tomography (PET) and positron emission mammography (PEM) and combinations of techniques (e.g. PET-CT and multiparametric PET-MRI). Methodical innovations Recently, novel techniques for molecular imaging of breast tumors, such as sodium imaging (23Na-MRI), phosphorus spectroscopy (31P-MRSI) and hyperpolarized MRI as well as specific radiotracers have been developed and are currently under investigation. Practical recommendations It can be expected that molecular imaging of breast tumors will enable a simultaneous assessment of the multiple metabolic and molecular processes involved in cancer development and thus an improved detection, characterization, staging and monitoring of response to treatment will become possible.